Ensysce Biosciences, INC. (ENSCW) — 8-K Filings

8-K Filings (16)

• 8-K Filing — Nov 17, 2025
• Ensysce Biosciences Changes Auditors to BDO USA, LLP — Jun 5, 2025 Risk: low
  Ensysce Biosciences, Inc. filed an 8-K on June 5, 2025, reporting a change in its certifying accountant. The company previously engaged WithumSmith+Brown, PC, b
• Ensysce Biosciences Files 8-K on Operations — May 13, 2025 Risk: low
  Ensysce Biosciences, Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhi
• Ensysce Biosciences Files 8-K: Material Agreement & Equity Sales — Apr 24, 2025 Risk: medium
  Ensysce Biosciences, Inc. announced on April 23, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of
• Ensysce Biosciences Files 8-K — Apr 1, 2025 Risk: low
  Ensysce Biosciences, Inc. filed an 8-K on April 1, 2025, reporting other events and financial statements. The company, formerly known as Leisure Acquisition Cor
• Ensysce Biosciences Enters Material Definitive Agreement — Mar 31, 2025 Risk: medium
  On March 30, 2025, Ensysce Biosciences, Inc. entered into a Material Definitive Agreement related to unregistered sales of equity securities. The company, forme
• Ensysce Biosciences Enters Material Definitive Agreement — Feb 4, 2025 Risk: medium
  Ensysce Biosciences, Inc. announced on February 4, 2025, that it entered into a material definitive agreement. The filing does not specify the other party or th
• Ensysce Biosciences Files 8-K for Bylaw Amendments — Dec 3, 2024 Risk: low
  Ensysce Biosciences, Inc. filed an 8-K on December 3, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The filing
• Ensysce Biosciences Files 8-K on Security Holder Vote — Nov 21, 2024 Risk: medium
  Ensysce Biosciences, Inc. filed an 8-K on November 21, 2024, to report on the submission of matters to a vote of its security holders. The filing indicates that
• Ensysce Biosciences Files 8-K for Bylaw Amendments & Financials — Oct 18, 2024 Risk: low
  Ensysce Biosciences, Inc. filed an 8-K on October 18, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The compan
• Ensysce Biosciences Files 8-K: Material Agreement, Equity Sales — Aug 30, 2024 Risk: medium
  Ensysce Biosciences, Inc. announced on August 29, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of
• Ensysce Biosciences Faces Nasdaq Delisting Warning — Aug 23, 2024 Risk: medium
  Ensysce Biosciences, Inc. announced on August 23, 2024, that it received a notice from The Nasdaq Stock Market on August 20, 2024, indicating non-compliance wit
• Ensysce Biosciences Files 8-K — May 28, 2024 Risk: low
  Ensysce Biosciences, Inc. filed an 8-K on May 28, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Leisure
• Ensysce Biosciences Sells Subsidiary for $10M Cash & Equity — May 9, 2024 Risk: medium
  Ensysce Biosciences, Inc. announced on May 9, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Ensysce Health, Inc., t
• Ensysce Biosciences Faces Delisting Concerns — Mar 29, 2024 Risk: high
  Ensysce Biosciences, Inc. filed an 8-K on March 29, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event rep
• Ensysce Biosciences Reports Equity Sales & Material Agreement — Feb 14, 2024 Risk: medium
  On February 12, 2024, Ensysce Biosciences, Inc. entered into a material definitive agreement and completed unregistered sales of equity securities. This 8-K fil

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX